• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.390 +0.020 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,181
Open 1.370
Bid (Size) 1.360 (200)
Ask (Size) 1.380 (900)
Prev. Close 1.370
Today's Range 1.340 - 1.390
52wk Range 1.000 - 6.230
Shares Outstanding 3,504,950
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis
April 21, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 20, 2026
Via Investor Brand Network

Performance

YTD
-2.1%
-2.1%
1 Month
+14.9%
+14.9%
3 Month
+7.8%
+7.8%
6 Month
-10.9%
-10.9%
1 Year
-35.9%
-35.9%

More News

Read More
Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 17, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
April 16, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook
April 15, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
April 14, 2026
Via Investor Brand Network
News headline image
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 10, 2026
Via ACCESS Newswire
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
April 02, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication
April 01, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition
March 31, 2026
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
March 31, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
March 26, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
March 24, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer
March 23, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
March 23, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
March 20, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication
March 19, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points
March 19, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline
March 18, 2026
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
March 10, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development
March 09, 2026
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
March 05, 2026
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease
February 26, 2026
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit
February 24, 2026
Via Investor Brand Network
News headline image
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options
February 12, 2026
Via Investor Brand Network

Frequently Asked Questions

Is Soligenix, Inc. - Common Stock publicly traded?
Yes, Soligenix, Inc. - Common Stock is publicly traded.
What exchange does Soligenix, Inc. - Common Stock trade on?
Soligenix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soligenix, Inc. - Common Stock?
The ticker symbol for Soligenix, Inc. - Common Stock is SNGX on the Nasdaq Stock Market
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 1.390
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 4.87M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap